Abstract
The complex [Ru[9]aneS3(pdon)Cl]Cl (pdon = 1,10-phenanthroline-5,6-dione) was readily obtained from the stoichiometric reaction of Ru[9]aneS3(dmso)Cl2 with pdon. Recrystallisation in ethanol using salicylic acid as a co-crystallisation helper afforded single-crystals suitable for the collection of X-ray diffraction data which afforded a reasonable structural description. Two different kinds of molecular carriers were tested as vehicles for this complex: carbon nanotubes (CNTs) and cyclodextrins. CNTs had an insufficient loading rate for the ruthenium complex at CNT concentrations deemed non-cytotoxic on cultured cells. The cyclodextrin (CD) carriers, β-CD and TRIMEB (standing for permethylated β-CD), were able to form two adducts, studied by powder X-ray diffraction, thermogravimetric analysis (TGA), 13C{1H} CP/MAS NMR and FT-IR spectroscopies. The DNA thermal denaturation studies showed that the complex 1 is able to intercalate with DNA. The in vitro cytotoxicity of the free complex [Ru[9]aneS3(pdon)Cl]Cl (1) and of its two CD adducts (2 and 3) was assessed on both rodent and human cell lines. By using the mouse K1735-M2 melanoma cell line and the non-tumour rat H9c2 cardiomyoblasts, the results showed that 1 and 2 significantly inhibited the growth of the tumour cell line while displaying a good safety profile on cardiomyoblasts. Compound 3 at 100 μM inhibited the proliferation of both cell lines, with a higher activity towards the melanoma cell line. The cytotoxicity of the compounds 1–3 was further assessed on human breast cancer cell lines. Against the MDA-MB-231 line, growth inhibition occurred only with 1 and 3 at the incubation time of 96 h, both with approximate inhibition rates of 50 %; against the MCF-7 line, mild cytotoxicity was observed at 48 h of incubation, with IC50 values calculated above 100 μM for 1, 2 and 3.
Similar content being viewed by others
Abbreviations
- [9]aneS3 :
-
1,4,7-Trithiacyclononane
- ANOVA:
-
Analysis of variance
- CD:
-
Cyclodextrin
- CNT:
-
Carbon nanotube
- CP/MAS:
-
Cross-polarisation with magic-angle spinning
- DMEM:
-
Dulbecco’s modified eagle’s medium
- dmso:
-
Dimethylsulfoxide
- DNA:
-
Deoxyribonucleic acid
- dppz:
-
Dipyrido[3,2-a:2′,3′-c]phenazine
- EDTA:
-
Ethylenediaminetetraacetic acid
- EAT:
-
Ehrlich ascites tumour
- EtOH:
-
Ethanol
- FBS:
-
Fetal bovine serum
- FT-IR:
-
Fourier-transform infrared spectroscopy
- H9c2:
-
Non-tumoural H9c2 cardiomyoblast cell line
- IC50 :
-
Half maximal inhibitory concentration
- K1735-M2:
-
Mouse melanoma cell line
- MCF-7:
-
Human epithelial breast adenocarcinoma cell line (estrogen dependent)
- MDA-MB-231:
-
Human epithelial breast adenocarcinoma cell line (estrogen independent)
- MTT:
-
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
- NMR:
-
Nuclear magnetic resonance
- oxCNT:
-
Oxidised carbon nanotube
- PBS:
-
Phosphate buffered saline
- phen:
-
1,10-Phenanthroline
- pdon:
-
1,10-Phenanthroline-5,6-dione
- SRB:
-
Sulforhodamine B
- TGA:
-
Thermogravimetric analysis
- XRD:
-
X-ray diffraction
References
Alanyali FS, Ergin E, Artagan O, Benkli K (2011) Investigation of genotoxic effects of some ruthenium complexes according to cis-platinum. Int J Pharmacol 7:96–105
Ali-Boucetta H, Al-Jamal KT, McCarthy D, Prato M, Bianco A, Kostarelos K (2008) Multiwalled carbon nanotube-doxorubicin supramolecular complexes for cancer therapeutics. Chem Commun 4:459–461
Allen TM, Cullis PR (2004) Drug delivery systems: entering the mainstream. Science 303:1818–1822
APEX2 (2006). Data Collection Software Version 21-RC13, Bruker AXS, Delft, The Netherlands
Arlt M, Haase D, Hampel S, Oswald S, Bachmatiuk A, Klingeler R, Schulze R, Ritschel M, Leonhardt A, Fuessel S, Büchner B, Kraemer K, Wirth MP (2010) Delivery of carboplatin by carbon-based nanocontainers mediates increased cancer cell death. Nanotechol 21:335101
Barroug A, Glimcher MJ (2002) Hydroxyapatite crystals as a local delivery system for cisplatin: adsorption and release of cisplatin in vitro. J Orthop Res 20:274–280
Braga SS, Gonçalves IS, Pillinger M, Ribeiro-Claro P, Teixeira-Dias JJC (2001) Experimental and theoretical study of the interaction of molybdenocene dichloride (Cp2MoCl2) with β-cyclodextrin. J Organomet Chem 632:11–16
Braga SS, Gonçalves IS, Herdtweck E, Teixeira-Dias JJC (2003a) Solid state inclusion compound of S-ibuprofen in β-cyclodextrin: structure and characterization. New J Chem 27:597–601
Braga SS, Ribeiro-Claro P, Pillinger M, Gonçalves IS, Pereira F, Fernandes AC, Romão CC, Correia PB, Teixeira-Dias JJC (2003b) Encapsulation of sodium nimesulide and precursors in β-cyclodextrin. Org Biomol Chem 1:873–878
Braga SS, Ribeiro-Claro P, Pillinger M, Gonçalves IS, Fernandes AC, Pereira F, Romão CC, Correia PB, Teixeira-Dias JJC (2003c) Interactions of omeprazole and precursors with beta-cyclodextrin host molecules. J Incl Phenom Macrocycl Chem 47:47–52
Braga SS, Paz FAA, Pillinger M, Seixas JD, Romão CC, Gonçalves IS (2006) Structural studies of β-cyclodextrin and permethylated β-cyclodextrin inclusion compounds of cyclopentadienyl metal carbonyl complexes. Eur J Inorg Chem 8:1662–1669
Branco AF, Pereira SL, Moreira AC, Holy J, Sardão VA, Oliveira PJ (2011) Isoproterenol cytotoxicity is dependent on the differentiation state of the cardiomyoblast H9c2 cell line. Cardiovasc Toxicol 11:191–203
Branco AF, Sampaio SF, Moreira AC, Holy J, Wallace KB, Baldeiras I, Oliveira PJ, Sardão VA (2012) Differentiation-dependent doxorubicin toxicity on H9c2 cardiomyoblasts. Cardiovasc Toxicol 12:326–340
Brandenburg K (1997-2010) DIAMOND, Version 32f Crystal Impact GbR, Bonn, Germany
Brechin EK, Calucci L, Englert U, Margheriti L, Pampaloni G, Pinzino C, Prescimone A (2008) 1,10-Phenanthroline-5,6-dione complexes of middle transition elements: mono- and di-nuclear derivatives. Inorg Chim Acta 361:2375–2384
Bruno S, Fernandes JA, Marques J, Neto SC, Ribeiro-Claro PJ, Pillinger M, Paz FAA, Marques MPM, Braga SS, Gonçalves IS (2011) Structural studies and cytotoxicity of trimethyl(ferrocenylmethyl)ammonium iodide encapsulated in beta-cyclodextrin. Eur J Inorg Chem 32:4955–4963
Caira MR (2001) On the isostructurality of cyclodextrin inclusion complexes and its practical utility. Rev Roum Chim 46:371–386
Caira MR, Bourne SA, Mhlongo WT, Dean PM (2004) New crystalline forms of permethylated beta-cyclodextrin. Chem Commun 2004:2216–2217
Chen J-F, Ding H-M, Wang J-X, Shao L (2004) Preparation and characterization of porous hollow silica nanoparticles for drug delivery application. Biomaterials 25:723–727
Cryopad (2006). Remote monitoring and control, Version 1451, Oxford Cryosystems, Oxford, United Kingdom
Davis ME, Brewster ME (2004) Cyclodextrin-based pharmaceuticals: past, present and future. Nature Rev 3:1023–1035
Deegan C, Coyle B, McCann M, Devereux M, Egan DA (2006) In vitro anti-tumour effect of 1,10-phenanthroline-5,6-dione (phendione), [Cu(phendione)3](ClO4)2·4H2O and [Ag(phendione)2]ClO4 using human epithelial cell lines. Chem Biol Interact 164:115–125
Dikmen M, Benkli K, Ozturk Y (2011) Inhibition of C6 glioma cell proliferation by Au(III) and Pt(II) complexes of 1,10-phenanthroline-5,6-dione. Asian J Chem 23:2749–2754
Fernandes JA, Lima S, Braga SS, Ribeiro-Claro P, Rodriguez-Borges JE, Teixeira C, Pillinger M, Teixeira-Dias JJC, Gonçalves IS (2005) Inclusion complex formation of diferrocenyldimethylsilane with β-cyclodextrin. J Organomet Chem 690:4801–4808
Frodl A, Herebian D, Sheldrick WS (2002) Coligand tuning of the DNA binding properties of bioorganometallic (η6-arene)ruthenium(II) complexes of the type [(η6-arene)-Ru(amino acid)(dppz)]n+ (dppz = dipyrido[3,2-a:2′,3′-c]phenazine), n = 1–3. J Chem Soc Dalton Trans 19:3664–3673
Goodfellow BJ, Félix V, Pacheco SMD, de Jesus JP, Drew MGB (1997) Structural characterisation of Ru(II) [9]aneS3 polypyridyl complexes by NMR spectroscopy and single-crystal X-ray diffraction. Polyhedron 16:393–401
Goss CA, Abruña HD (1985) Spectral, electrochemical, and electrocatalytic properties of 1,10-phenanthroline-5,6-dione complexes of transition metals. Inorg Chem 24:4263–4267
Guven A, Rusakova IA, Lewis MT, Wilson LJ (2012) Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials 33:1455–1461
Harada A, Saeki K, Takahashi S (1989) Preparation and properties of inclusion compounds of (η6-Arene)tricarbonylcromium(0) complexes with cyclodextrins. Organometallics 8:730–733
Heister E, Lamprecht C, Neves V, Tilmaciu C, Datas L, Flahaut E, Soula B, Hinterdorfer P, Coley HM, Silva SR, McFadden J (2010) Higher dispersion efficacy of functionalized carbon nanotubes in chemical and biological environments. ACS Nano 4:2615–2626
Heister E, Neves V, Lamprecht C, Silva SR, Coley HM, McFadden J (2012) Drug loading, dispersion stability, and therapeutic efficacy in targeted drug delivery with carbon nanotubes. Carbon 50:622–632
Hilder TA, Hill JM (2008) Carbon nanotubes as drug delivery nanocapsules. Curr Appl Phys 3–4:258–261
Huang HC, Barua S, Sharma G, Dey SK, Rege K (2011) Inorganic nanoparticles for cancer imaging and therapy. J Controlled Release 155(3):344–357
Kottke T, Stalke D (1993) Crystal handling at low-temperatures. J App Cryst 26:615–619
Kumar KA, Reddy KL, Vidhisha S, Satyanarayana S (2009) Synthesis, characterization and DNA binding and photocleavage studies of [Ru(bpy)2BDPPZ]2+, [Ru(dmb)2BDPPZ]2+ and [Ru(phen)2BDPPZ]2+ complexes and their antimicrobial activity. Appl Organomet Chem 23:409–420
Larsson K, Öhrström L (2004) X-ray and NMR study of the fate of the Co(1,10-phenanthroline-5,6-diketone)3+ ion in aqueous solution: supramolecular motifs in the packing 1,10-phenanthroline-5,6-diketone and 1,10-phenanthroline-5,6-diol complexes. Inorg Chim Acta 357:657–664
Lin FH, Lee YH, Jian CH, Wong J-M, Shieh M-J, Wang C-Y (2002) A study of purified montmorillonite intercalated with 5-fluorouracil as drug carrier. Biomaterials 23:1981–1987
Madureira J, Santos TM, de Jesus JP, Goodfellow BJ, Santana-Marques MG, Lucena M, Drew MGB (2000) Structural characterisation of new RuII[9]aneS3 polypyridylic complexes. J Chem Soc Dalton Trans 23:4422–4431
Marques J, Anjo L, Marques MPM, Santos TM, Paz FAA, Braga SS (2008) Structural studies on supramolecular adducts of cyclodextrins with the complex [Ru([9]aneS3)(bpy)Cl]Cl. J Organomet Chem 693:3021–3028
Marques J, Braga TM, Paz FAA, Santos TM, Lopes MFS, Braga SS (2009a) Cyclodextrins improve the antimicrobial Activity of the chloride salt of Ruthenium(II) chloro-phenanthroline-trithiacyclononane. Biometals 22:541–556
Marques J, Santos TM, Marques MPM, Braga SS (2009b) A glycine ruthenium trithiacyclononane complex and its molecular encapsulation using cyclodextrins. Dalton Trans 44:9812–9819
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Nakamoto K (1966) Infrared spectra of inorganic and co-ordination compounds. M. Mir, Moscow
Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH (1997) Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 208:151–158
Parveen S, Misra R, Sahoo SK (2012) Nanoparticles: a boom to drug delivery, therapeutics, diagnostics and imaging. Nanomed Nanotechnol Biol Med 8:147–166
Pereira CCL, Nolasco M, Braga SS, Paz FAA, Ribeiro-Claro P, Pillinger M, Gonçalves IS (2007) A combined theoretical-experimental study of the inclusion of niobocene dichloride in native and permethylated β-cyclodextrins. Organometallics 26:4220–4228
Petrovski Ž, Braga SS, Rodrigues SS, Pereira CCL, Gonçalves IS, Pillinger M, Freire C, Romão CC (2005a) Synthesis of ferrocenyldiimine metal carbonyl complexes and an investigation of the Mo adduct encapsulated in cyclodextrin. New J Chem 29:347–354
Petrovski Ž, Braga SS, Santos AM, Rodrigues SS, Gonçalves IS, Pillinger M, Kühn FE, Romão CC (2005b) Synthesis and characterization of the inclusion compound of a ferrocenyldiimine dioxomolybdenum complex with heptakis-2,3,6-tri-O-methyl-beta-cyclodextrin. Inorg Chim Acta 358:981–988
Radin S, Ducheyne P, Kamplain T, Tan BH (2001) Silica sol–gel for the controlled release of antibiotics. I. Synthesis, characterization, and in vitro release. J Biomed Mater Res 57:313–320
Ramos AI, Braga TM, Silva P, Fernandes JA, Ribeiro-Claro P, Lopes MFS, Paz FAA, Braga SS (2012) Chloramphenicol·cyclodextrin inclusion compounds: co-dissolution and mechanochemical preparations and antibacterial action. CrystEngComm 15:2822–2834
Roseanu A, Florian PE, Moisei E, Sima LE, Evans RW, Trif M (2010) Liposomalization of lactoferrin enhanced its anti-tumoral effects on melanoma cells. Biometals 23:485–492
Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, Dougherty TJ, Prasad PN (2003) Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125:7860–7865
Roy S, Hagen KD, Maheswari PU, Lutz M, Spek AL, Reedijk J, van Wezel GP (2008) Phenanthroline derivatives with improved selectivity as DNA-targeting anticancer or antimicrobial drugs. ChemMedChem 3:1427–1434
SAINT+ (1997–2005). Data Integration Engine v 723a ©:Bruker AXS, Madison, Wisconsin, USA
Santos TM, Madureira J, Goodfellow BJ, Drew MGB, de Jesus JP, Félix V (2001) Interaction of Ruthenium(II)-dipyridophenazine complexes with CT-DNA: effects of the polyhioether ancillary ligands. Met Based-Drugs 8:125–135
Sardão VA, Oliveira PJ, Holy J, Oliveira CR, Wallace KB (2009) Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts. Cancer Chemother Pharmacol 64:811–827
Sheldrick GM (1997a) SHELXS-97, Program for Crystal Structure Solution, University of Göttingen
Sheldrick GM (1997b) SHELXL-97, Program for Crystal Structure Refinement, University of Göttingen
Sheldrick GM (1998) SADABS v201, Bruker/Siemens Area Detector Absorption Correction Program, Bruker AXS, Madison, WI, USA
Sheldrick GM (2008) A short history of SHELX. Acta Cryst A 64:112–122
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112
Spek AL (1990) PLATON. Acta Cryst A 46:C34
Spek AL (2003) Single-crystal structure validation with the program PLATON. J Appl Crystallogr 36:7–13
Szejtli J (1998) Cyclodextrin and general overview of cyclodextrin chemistry. Chem Rev 98:1743–1754
van der Sluis P, Spek AL (1990) Acta Cryst A 46:194–201
Wagner A, Vorauer-Uhl K (2011) Liposome technology for industrial purposes. J Drug Deliv 2011:591325. doi:10.1155/2011/591325
Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand J-P, Gennaro R, Prato M, Bianco A (2005) Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed 44:6358–6362
Acknowledgments
The supply of β-CD (Kleptose) by Roquette Laboratoires (Lestrem, France) is gracefully acknowledged. We are also grateful to Fundação para a Ciência e a Tecnologia (FCT, Portugal), European Union, QREN, European Fund for Regional Development (FEDER), through the programme COMPETE, for general funding to the QOPNA research unit (project PEst C-QUI/UI0062/2013; FCOMP-01-0124-FEDER-037296), to the Associated Laboratory CICECO (PEst C-CTM/LA0011/2013) and to the CNC (PEst-C/SAU/LA0001/2013-2014), and for specific funding towards the purchase of the single-crystal diffractometer. The FCT and the European Social Fund, through the Programa Operacional Potencial Humano (POPH), are acknowledged for a PhD grant to J. M. (SFRH/BD/44791/2008).
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Braga, S.S., Marques, J., Heister, E. et al. Carriers for metal complexes on tumour cells: the effect of cyclodextrins vs CNTs on the model guest phenanthroline-5,6-dione trithiacyclononane ruthenium(II) chloride. Biometals 27, 507–525 (2014). https://doi.org/10.1007/s10534-014-9725-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10534-014-9725-8